English

Choose language

Back

  • Deutsch

  • ελληνική

  • English

  • Español

  • Français

  • Polski

  • Português

  • Русский

  • Українська


English

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

AstraZeneca Stock: 12% Yield Potential due to COVID-19 Vaccine Prospects

Company name: AstraZeneca
Ticker: AZN.US (New York Stock Exchange)
Target Price: $62
Projected Yield: 12%
Time Line: 3 to 6 months
Risk: Average

About AstraZeneca

AstraZeneca is a pharmaceutical holding based in the UK and Sweden, which focuses on researching and producing pharmaceuticals. The core business is oncology treatment and internal medicine, while the company is also developing a vaccine against COVID-19.

What's the Idea?

Capitalize on the stock that could rise with COVID-19 vaccine development and the growth in cancer drugs sales.


Buy AstraZeneca Shares >>


Why Trade AstraZeneca?

Reason 1: Development of a COVID-19 Vaccine

The company's stock price is significantly influenced by the news about developing a vaccine against COVID-19. AstraZeneca is working on it in collaboration with the University of Oxford. This vaccine is considered one of the most promising and is currently undergoing stage 3 of clinical trials.

Reason 2: Vaccine Supply Contracts

AstraZeneca has already entered into a number of agreements for vaccine supply, including those in the US, the UK, the EU, India, Brazil, Argentina, and Mexico. With a total amount of 1.10 billion doses, the average price per dose is around $4.00. Other countries may also join this list. The implementation of the concluded contracts can increase the company's annual earnings by over 18%.

Reason 3: Excellent Financial Results

AstraZeneca posted positive financial results for the first six months of 2020. Sales of cancer drugs in Q2 were up by 29.50% YoY, with the three major cancer drugs posting earnings growth of 32%, 46%, and 48%. This trend may continue, as the global cancer incidence rate is not decreasing.

The company's strategy of increasing new drug sales is working successfully: in the first six months of 2020, new drugs accounted for 50% of total earnings, up from 40% a year before.

How to Use the Investment Idea

  1. Buy AstraZeneca shares at the current price.
  2. Allocate no more than 3% to 4% of your midterm transaction budget.
  3. Sell the stock when the price is at $62 per share.

How to Buy AstraZeneca Shares?

If you don't have an investment account yet, open it now: this can be done online, in just 10 minutes. All you need to do is fill out a short form and verify your account.

After opening an account, you can buy shares in either of the following ways:

Freedom24 Web Platform: Go to the Web Terminal section, type AZN.US (AstraZeneca ticker in the NYSE) in the search box, and select AstraZeneca PLC ADS. in the search results. Open a secure session in the trading window on the right, select the number of shares you want to buy, and click Buy.

Freedom24 iPhone App: Go to the Price screen and tab the search icon in the top right corner. In the search dialog that shows up, type AZN.US (AstraZeneca ticker in the NYSE), and select AstraZeneca PLC ADS in the search results. You will then see AstraZeneca stock in the market watch; tap it and go to the Order tab in the dialog that shows up. Specify the number of shares you want to buy and click Buy.

Buy AstraZeneca Stock: Don't Miss the Opportunity to Capitalize on COVID-19 Vaccine!


Buy AstraZeneca Shares >>


*Additional information is available upon request. Investment in securities and other financial instruments always involves risks of capital loss. The Client should make himself aware at his own accord, including to familiarize himself with Risk Disclosure Notice. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Commissions, fees or other charges can diminish financial returns. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and do not constitute an investment advice service. The recipient of this report must make their own independent decisions regarding any securities or financial instruments mentioned herein. Information has been obtained from sources believed to be reliable by Freedom Finance Cyprus Ltd or its affiliates and/or subsidiaries (collectively Freedom Finance). Freedom Finance do not warrant its completeness or accuracy except with respect to any disclosures relative to the Freedom Finance and/or its affiliates and the analyst’s involvement with the issuer that is the subject of the research. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated.